Abstract:To the Editor: A 35-year-old man who smoked for 15 years suffered from chest pain 12 days ago before admission. He was diagnosed as myocardial infarction. Thrombolytic therapy was given consequently. The electrocardiogram showed sub-acute inferior wall myocardial infarction. Echocardiogram showed attenuated constriction of the inferior wall with an ejection fraction of 59%. On September 5, 2013, he was treated with a XINSORB scaffold in right coronary artery (RCA). Angiography revealed a regional lesion with severe stenosis in the distal RCA. No lesions were detected in the rest segment of coronary arteries [Figure 1a]. Intravascular ultrasound (IVUS) confirmed abundant fibrous plaques with plaque rupture in the lesion site [Figure 1b]. After predilatation, a XINSORB scaffold whose size was 3.0 mm × 18.0 mm was implanted. Repeated angiography showed the scaffold was well deployed. Minimal luminal diameter (MLD) was 2.95 mm while in-scaffold residual stenosis was 7.4% [Figure 1c]. No malapposition was detected under IVUS [Figure 1d]. The scaffold area was 6.62 ± 0.57 mm2. The patient was discharged 2 days after the procedure. Neither major adverse cardiac events nor stent thrombus related events were recorded. During the next 6 months, the patient recovered well without recurrent ischemic symptoms. Dual antiplatelet therapy was maintained. Angiography at 6-month follow-up showed the scaffold remained patent without significant neointimal hyperplasia. In-scaffold MLD and percent of diameter stenosis was 2.73 mm and 8.8% respectively, therefore the in-scaffold late luminal loss was calculated as 0.22 mm [Figure 1e]. The area of scaffold, lumen and neointima was 6.69 ± 0.52 mm2, 6.44 ± 0.46 mm2 and 0.24 ± 0.11 mm2 under IVUS [Figure 1f]. No difference was detected between the scaffold area after the procedure and 6-month follow-up (P = 0.82). Optical coherence tomography showed that all struts remained the appearance of preserved box. The struts were embedded in neointima and well-apposed. Figure 1 (a and b) Regional lesion with severe stenosis in the distal RCA; IVUS showed abundant fibrous plaques; (c and d) Final result after treated with a XINSORB scaffold; the struts were well apposed under IVUS; (e and f) The vessel remained patent at 6-month ... Bioresorbable XINSORB scaffold is a balloon-expandable stent system. The scaffold is composed of poly-L-lactic acid (PLLA) as its backbone. Poly-D-L-lactic acid mixed with PLLA is coated on the scaffold surface, containing sirolimus and controlling its elution. The dose of sirolimus is 8 μg/mm. About 80% of anti-proliferative drugs are eluted in 28 days ex vivo. Thickness of strut is 160 μm. The device is stored at 4°C.[1,2] The safety and effectiveness of bioresorbable scaffold (BRS) are confirmed by ABSORB studies.[3,4,5] The XINSORB scaffold is the first domestically made BRS by Chinese company. Promising clinical and angiographic outcomes have been established in this patient. Some advice should be followed when using this device. First, mandatory predilatation must be performed. A balloon to artery ratio of 1:1 is recommended. Second, the scaffold should not be deployed until 90 s after it exposes to the blood. Third, the scaffold should be slowly expanded from 0 to 4 atm during the first 10 s. After that, the scaffold can be fully expanded at a pressure not exceeding 14 atm for 30 s. Lastly, postdilatation was allowed with a 3.0 mm or 3.25 mm noncompliance balloon that was shorter than the implanted scaffold. This is the first implantation of a domestic BRS. Currently, a single-arm clinical trial of XINSORB scaffold is being carried out in Zhongshan Hospital, Fudan University and Chinese People's Liberation Army General Hospital. Large scale and long-term follow-up are required to confirm the substantial benefits of XINSORB scaffold in treating coronary lesions of Chinese population.

5 Years of Serial Intravascular Imaging Outcomes of XINSORB Sirolimus-Eluting Bioresorbable Vascular Scaffold.

Six-month Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold in Treating Single De Novo Lesions in Human Coronary Artery.

Three‐year Clinical Outcomes of the Novel Sirolimus‐eluting Bioresorbable Scaffold for the Treatment of De Novo Coronary Artery Disease: A Prospective Patient‐level Pooled Analysis of NeoVas Trials

Three-year Clinical Outcomes of a Sirolimus-Eluting Bioresorbable Scaffold (XINSORB) and a Metallic Stent to Treat Coronary Artery Stenosis.

Final Report of the 5-Year Clinical Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold in the Treatment of Single De Novo Coronary Lesions in a First-in-human Study

Twelve-month Angiographic and Clinical Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold and a Metallic Stent in Patients with Coronary Artery Disease

First-in-man Implantation of the XINSORB Bioresorbable Sirolimus-eluting Scaffold in China

Comparison of the “late Catch-Up” Phenomenon Between BuMA Supreme and XIENCE Stents Through Serial Optical Coherence Tomography at 1–2 Month and 2 Year Follow-Ups: A Multicenter Study

Healing Score of the Xinsorb Scaffold in the Treatment of De Novo Lesions: 6-Month Imaging Outcomes

TCT-431 Long-term Angiographic and Optical Coherence Tomography Follow-up of XINSORB Scaffold in Porcine Coronary Model

A Head to Head Comparison of XINSORB Bioresorbable Sirolimus-Eluting Scaffold Versus Metallic Sirolimus-Eluting Stent: 180 Days Follow-Up in a Porcine Model

Short-term Efficacy of Fully Bioabsorbable Poly-L-Lactic Acid Sirolimus-eluting Scaffold in Porcine Model Assessed by Optical Coherence Tomography

First‐in‐man Study of a Thinner‐strut Sirolimus‐eluting Bioresorbable Scaffold (FUTURE‐I): Three‐year Clinical and Imaging Outcomes

Long‐term Clinical, Angiographic, and Intravascular Ultrasound Outcomes of Biodegradable Polymer‐coated Sirolimus‐eluting Stents

One-year Clinical Outcomes and Multislice Computed Tomography Angiographic Results Following Implantation of the NeoVas Bioresorbable Sirolimus-Eluting Scaffold in Patients with Single De Novo Coronary Artery Lesions

Long-Term Efficacy, Safety and Biocompatibility of a Novel Sirolimus Eluting Iron Bioresorbable Scaffold in a Porcine Model

TCT-430 Nine-Month Angiographic and 1-Year Clinical Outcomes of the RECOVERY Study: A Randomized Trial Evaluating the Safety and Efficacy of the Combo Bio-Engineered Sirolimus-Eluting Stent Versus the Nano Polymer-Free Sirolimus-Eluting Stent in Patients with Coronary Artery Disease

Clinical and multimodality imaging results at 6 months of a bioresorbable sirolimus-eluting scaffold for patients with single de novo coronary artery lesions: the NeoVas first-in-man trial.

Impact Of Angiographic And Intravascular Ultrasound Features On Clinical Outcome After Sirolimus-Eluting Stent Implantation For De-Novo Lesions In Nondiabetic And Type 2 Diabetic Patients

Long-Term Safety of an Everolimus-Eluting Bioresorbable Vascular Scaffold and the Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model

Short and Intermediate Term Clinical Outcome of Sirolimus-Eluting Stent Implantation in Patients with ST-segment Elevation Myocardial Infarction